298 related articles for article (PubMed ID: 18583569)
1. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.
Beers SA; Chan CH; James S; French RR; Attfield KE; Brennan CM; Ahuja A; Shlomchik MJ; Cragg MS; Glennie MJ
Blood; 2008 Nov; 112(10):4170-7. PubMed ID: 18583569
[TBL] [Abstract][Full Text] [Related]
2. Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies.
Beurskens FJ; Ruuls SR; Engelberts PJ; Vink T; Mackus WJ; van de Winkel JG; Parren PW
Blood; 2008 Nov; 112(10):4354-5; author reply 4355-6. PubMed ID: 18988880
[No Abstract] [Full Text] [Related]
3. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Beers SA; French RR; Chan HT; Lim SH; Jarrett TC; Vidal RM; Wijayaweera SS; Dixon SV; Kim H; Cox KL; Kerr JP; Johnston DA; Johnson PW; Verbeek JS; Glennie MJ; Cragg MS
Blood; 2010 Jun; 115(25):5191-201. PubMed ID: 20223920
[TBL] [Abstract][Full Text] [Related]
4. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
5. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
[TBL] [Abstract][Full Text] [Related]
6. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.
Cragg MS; Glennie MJ
Blood; 2004 Apr; 103(7):2738-43. PubMed ID: 14551143
[TBL] [Abstract][Full Text] [Related]
7. Engineered antibodies with increased activity to recruit complement.
Idusogie EE; Wong PY; Presta LG; Gazzano-Santoro H; Totpal K; Ultsch M; Mulkerrin MG
J Immunol; 2001 Feb; 166(4):2571-5. PubMed ID: 11160318
[TBL] [Abstract][Full Text] [Related]
8. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
Xiu Y; Wong CP; Bouaziz JD; Hamaguchi Y; Wang Y; Pop SM; Tisch RM; Tedder TF
J Immunol; 2008 Mar; 180(5):2863-75. PubMed ID: 18292508
[TBL] [Abstract][Full Text] [Related]
9. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
10. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
11. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
[TBL] [Abstract][Full Text] [Related]
12. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
13. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.
Tipton TR; Roghanian A; Oldham RJ; Carter MJ; Cox KL; Mockridge CI; French RR; Dahal LN; Duriez PJ; Hargreaves PG; Cragg MS; Beers SA
Blood; 2015 Mar; 125(12):1901-9. PubMed ID: 25631769
[TBL] [Abstract][Full Text] [Related]
14. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
[TBL] [Abstract][Full Text] [Related]
15. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
[TBL] [Abstract][Full Text] [Related]
16. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R
Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394
[TBL] [Abstract][Full Text] [Related]
17. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
18. Complement activation determines the therapeutic activity of rituximab in vivo.
Di Gaetano N; Cittera E; Nota R; Vecchi A; Grieco V; Scanziani E; Botto M; Introna M; Golay J
J Immunol; 2003 Aug; 171(3):1581-7. PubMed ID: 12874252
[TBL] [Abstract][Full Text] [Related]
19. [Rituximab: mechanism of action and resistance].
Dalle S; Dumontet C
Bull Cancer; 2007 Feb; 94(2):198-202. PubMed ID: 17337389
[TBL] [Abstract][Full Text] [Related]
20. IgG2m4, an engineered antibody isotype with reduced Fc function.
An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
